Actively Recruiting
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
Led by Bristol-Myers Squibb · Updated on 2025-12-01
200
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy
CONDITIONS
Official Title
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants have started deucravacitinib monotherapy 4 to 8 weeks earlier following clinical practice and national reimbursement rules in Italy
- Patients with moderate to severe plaque psoriasis
- Patients able to understand and sign an informed consent form
You will not qualify if you...
- Participation in another interventional study for moderate-to-severe psoriasis
- Inability to understand the study purpose or to sign the informed consent form
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Azienda Ospedaliera Universitaria Integrata Di Verona
Verona, Verona, Italy, 37126
Actively Recruiting
Research Team
B
BMS Study Connect Contact Center www.BMSStudyConnect.com
CONTACT
F
First line of the email MUST contain NCT # and Site #
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here